ArticleJournal of neuro-oncology2020
Tumor immune microenvironment is associated with the growth of intracranial germinomas.
Article in Journal of neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 9 citations in OpenAlex.
- Crosstalk of cancer stemness-neutrophils in outcome of intracranial germ cell tumors.Frontiers in immunology · 2026Article
- CNS Germ Cell Tumors: Molecular Advances, Significance in Risk Stratification and Future Directions.Brain sciences · 2024Review
- Advances in genetic abnormalities, epigenetic reprogramming, and immune landscape of intracranial germ cell tumors.Acta neuropathologica communications · 2023Review
- High endothelial venules in intracranial germinomas: Implications for lymphocytes infiltration.Cancer medicine · 2023Article
- A case of germinoma located in the fornix inducing transsynaptic atrophy of the Papez circuit.Radiology case reports · 2023Article
- The features of acute lymphocytic leukemia with intracranial germinoma in a patient with Li-Fraumeni syndrome: a case description.Quantitative imaging in medicine and surgery · 2022Article
- Molecular Pathology and Targeted Therapies for Personalized Management of Central Nervous System Germinoma.Journal of personalized medicine · 2021Review
- Low tumor cell content predicts favorable prognosis in germinoma patients.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe role of immune checkpoint molecules and the tumor immune microenvironment in the development of intracranial germ cell tumors remains unclear.
methodsWe investigated the expression of programed cell death-1 (PD-1), programed cell death ligand-1 (PD-L1), and tumor-infiltrating lymphocytes (TILs) in 8 patients who had intracranial germinomas with sufficient tumor tissue by immunohistochemistry, to analyze the associations between their clinical courses and radiological features. The 8 patients were categorized based on the duration between symptom onset and pathological diagnosis into the long-term onset (LTO) group (> 1 year of symptoms) and the short-term onset (STO) group (< 1 year of symptoms).
resultsThree patients belonged to the LTO group and 5 patients to the STO group. Compared with STO tumors, LTO tumors were significantly associated with a lower ratio of PD-L1-positive tumor cells (p = 0.012), higher number of infiltrating CD3- and CD8-positive lymphocytes (p = 0.016, 0.003, respectively), and lower ratio of PD-1-positive cells per CD8-positive lymphocytes (p = 0.047). LTO germinomas were significantly smaller in size than STO tumors, not associated with hydrocephalus, and tended to be present in patients with older age at diagnosis and atypical tumor location.
conclusionsOur data suggest that the tumor immune microenvironment, including PD-1/PD-L1 signaling, is associated with the growth of intracranial germinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.